FDA Panel Votes For Theravance’s Telavancin, Against Targanta’s Oritavancin
This article was originally published in The Pink Sheet Daily
Executive Summary
Telavancin’s safety concerns did not stand in its way, but oritavancin’s efficacy concerns in treating MRSA did.
You may also be interested in...
Targanta’s Oritavancin Gets FDA “Complete Response”; Additional Phase III Needed
Agency requests Phase III study with MRSA subgroup: cost of additional study could lead company to seek development partner.
Targanta’s Oritavancin Gets FDA “Complete Response”; Additional Phase III Needed
Agency requests Phase III study with MRSA subgroup: cost of additional study could lead company to seek development partner.
J&J/Basilea's Ceftobiprole Faces Another Setback
A Nov. 26 FDA complete response letter to Johnson & Johnson and Basilea Pharmaceutica for their antibiotic ceftobiprole cites deficiencies of study conduct and requests further clinical site audits